Symptomatic therapy in multiple sclerosis: A review for a multimodal approach in clinical practice

Therapeutic Advances in Neurological Disorders

Volumn 4, Issue 3, 2011, Pages 139-168

  Jo, Joao Carlos Correia ^a   Airas, Laura ^b   Bartholome, Emmanuel ^c   Grigoriadis, Nikolaos ^d   Mattle, Heinrich ^e   Oreja Guevara, Celia ^f   Oriordan, Jonathan ^g   Sellebjerg, Finn ^h   Stankoff, Bruno ⁱ   Vass, Karl ^j   Walczak, Agata ^k   Wiendl, Heinz ^l   Kieseier, Bernd C ^m  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c Tivoli Hospital   (Belgium)

^d AHEPA UNIVERSITY HOSPITAL   (Greece)

^e UNIVERSITY OF BERN   (Switzerland)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g NHS TAYSIDE   (United Kingdom)

^h Rigshospitalet   (Denmark)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j UNIVERSITY OF VIENNA   (Austria)

^k MEDICAL UNIVERSITY OF LODZ   (Poland)

^l UNIVERSITY OF MÜNSTER   (Germany)

^m HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

clinical medicine; comorbidity; multiple sclerosis; neurology; review; signs and symptoms; therapy

Indexed keywords

4 AMINOPYRIDINE; AGENTS ACTING ON THE AUDITORY AND VESTIBULAR SYSTEMS; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; ANTICONVULSIVE AGENT; BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; DANTROLENE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; ISONIAZID; LUBRICATING AGENT; MISOPROSTOL; MODAFINIL; MUSCARINIC RECEPTOR BLOCKING AGENT; OXCARBAZEPINE; PHOSPHODIESTERASE V INHIBITOR; POTASSIUM CHANNEL BLOCKING AGENT; RIVASTIGMINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TETRAHYDROCANNABINOL; TIZANIDINE; TOLPERISONE; TOPIRAMATE; UNINDEXED DRUG;

AEROBIC EXERCISE; ANTICONVULSANT THERAPY; ATAXIA; COGNITIVE DEFECT; COGNITIVE THERAPY; CONFUSION; CONVULSION; COOLING; DAYTIME SOMNOLENCE; DECOMPRESSION SURGERY; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSARTHRIA; DYSPHAGIA; ENERGY CONSERVATION; ENTEROPATHY; ERECTILE DYSFUNCTION; FATIGUE; GAMMA KNIFE RADIOSURGERY; HUMAN; HYDROTHERAPY; LIBIDO DISORDER; MULTIPLE SCLEROSIS; NERVE DECOMPRESSION; NYSTAGMUS; OCCUPATIONAL THERAPY; PAIN; PALLIATIVE THERAPY; PARESTHESIA; PHYSIOTHERAPY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL DISORDER; RESTLESS LEGS SYNDROME; REVIEW; SEIZURE; SEXUAL DYSFUNCTION; SLEEP DISORDER; SPASTICITY; SPEECH THERAPY; SYSTEMATIC REVIEW; THERMOCOAGULATION; TREMOR; TRIGEMINUS NEURALGIA; UNSPECIFIED SIDE EFFECT; UNSTEADINESS; UROGENITAL TRACT DISEASE; VAGINAL DRYNESS; VERTIGO;

EID: 79956069870     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285611403646     Document Type: Review

References (290)

1. Abraham S. Scheinberg L.C. Smith C.R. LaRocca N.G. (1997) Neurologic impairment and disability status in outpatients with multiple sclerosis reporting dysphagia symptomatology. Neurorehabil Neural Repair 11: 7–13.
2. Albrecht H. Schwecht M. Pollmann W. Parag D. Erasmus L.P. Konig N. (1998) Local ice application in therapy of kinetic limb ataxia. Clinical assessment of positive treatment effects in patients with multiple sclerosis. Nervenarzt 69: 1066–1073.
3. Alusi S.H. Glickman S. Aziz T.Z. Bain P.G. (1999) Tremor in multiple sclerosis. J Neurol Neurosurg Psychiatry 66: 131–134.
4. Alusi S.H. Worthington J. Glickman S. Bain P.G. (2001) A study of tremor in multiple sclerosis. Brain 124: 720–730.
5. Amato M.P. Portaccio E. Goretti B. Zipoli V. Battaglini M. Bartolozzi M.L. et al (2007) Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol 64: 1157–1161.
6. Andreasen A.K. Jakobsen J. Soerensen L. Andersen H. Petersen T. Bjarkam C.R. et al (2010) Regional brain atrophy in primary fatigued patients with multiple sclerosis. Neuroimage 50: 608–615.
7. Araki I. Matsui M. Ozawa K. Takeda M. Kuno S. (2003) Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol 169: 1384–1387.
8. Arnett P.A. Higginson C.I. Voss W.D. Bender W.I. Wurst J.M. Tippin J.M. (1999) Depression in multiple sclerosis: relationship to working memory capacity. Neuropsychology 13: 546–556.
9. Ashworth B. (1964) Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 192: 540–542.
10. Atan A. Konety B.R. Nangia A. Chancellor M.B. (1999) Advantages and risks of ileovesicostomy for the management of neuropathic bladder. Urology 54: 636–640.
11. Audoin B. Guye M. Reuter F. Au Duong M.V. Confort-Gouny S. Malikova I. et al (2007) Structure of WM bundles constituting the working memory system in early multiple sclerosis: a quantitative DTI tractography study. Neuroimage 36: 1324–1330.
12. Avasarala J.R. Cross A.H. Trinkaus K. (2003) Comparative assessment of Yale Single Question and Beck Depression Inventory Scale in screening for depression in multiple sclerosis. Mult Scler 9: 307–310.
13. Averbuch-Heller L. Tusa R.J. Fuhry L. Rottach K.G. Ganser G.L. Heide W. et al (1997) A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol 41: 818–825.
14. Ayache S.S. Ahdab R. Neves D.O. Nguyen J.P. Lefaucheur J.P. (2009) Thalamic stimulation restores defective cerebellocortical inhibition in multiple sclerosis tremor. Mov Disord 24: 467–469.
15. Bain P.G. Findley L.J. Atchison P. Behari M. Vidailhet M. Gresty M. et al (1993) Assessing tremor severity. J Neurol Neurosurg Psychiatry 56: 868–873.
16. Bakshi R. Miletich R.S. Henschel K. Shaikh Z.A. Janardhan V. Wasay M. et al (1999) Fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients. Neurology 53: 1151–1153.
17. Bakshi R. Shaikh Z.A. Miletich R.S. Czarnecki D. Dmochowski J. Henschel K. et al (2000) Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 6: 181–185.
18. Bass B. Weinshenker B. Rice G.P. Noseworthy J.H. Cameron M.G. Hader W. et al (1988) Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 15: 15–19.
19. Basso M.R. Ghormley C. Lowery N. Combs D. Bornstein R.A. (2008) Self-generated learning in people with multiple sclerosis: an extension of Chiaravalloti and de Luca (2002). J Clin Exp Neuropsychol 30: 63–69.
20. Basso M.R. Lowery N. Ghormley C. Combs D. Johnson J. (2006) Self-generated learning in people with multiple sclerosis. J Int Neuropsychol Soc 12: 640–648.
21. Beard S. Hunn A. Wight J. (2003) Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 7: iii–iii. ix-iii, 111.
22. Beeney J.E. Arnett P.A. (2008) Endorsement of self-report neurovegetative items of depression is associated with multiple sclerosis disease symptoms. J Int Neuropsychol Soc 14: 1057–1062.
23. Benedict R.H. Duquin J.A. Jurgensen S. Rudick R.A. Feitcher J. Munschauer F.E. et al (2008) Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler 14: 940–946.
24. Benedict R.H. Fischer J.S. Archibald C.J. Arnett P.A. Beatty W.W. Bobholz J. et al (2002) Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol 16: 381–397.
25. Bergamaschi R. Romani A. Versino M. Poli R. Cosi V. (1997) Clinical aspects of fatigue in multiple sclerosis. Funct Neurol 12: 247–251.
26. Berk C. Constantoyannis C. Honey C.R. (2003) The treatment of trigeminal neuralgia in patients with multiple sclerosis using percutaneous radiofrequency rhizotomy. Can J Neurol Sci 30: 220–223.
27. Bermejo P.E. Oreja-Guevara C. Díez-Tejedor E. (2010) [Pain in multiple sclerosis: prevalence, mechanisms, types and treatment]. Rev Neurol 50: 101–108.
28. Betts C.D. (1999) Bladder And Sexual Dysfunction in Multiple Sclerosis. In: Ed. Fowler C.J. (ed.).Neurology of Bladder, Bowel, and Sexual Dysfunction: Blue Books of Practical Neurology, Butterworth-Heinemann: Boston, MA, 289–308.
29. Betts C.D. Jones S.J. Fowler C.G. Fowler C.J. (1994) Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition. Brain 117: 1303–1310.
30. Bever C.T. Jr. Anderson P.A. Leslie J. Panitch H.S. Dhib-Jalbut S. Khan O.A. et al (1996) Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 47: 1457–1462.
31. Bever C.T. Jr Young D. Anderson P.A. Krumholz A. Conway K. Leslie J. et al (1994) The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44: 1054–1059.
32. Birder L. de Groat W. Mills I. Morrison J. Thor K. Drake M. (2010) Neural control of the lower urinary tract: peripheral and spinal mechanisms. Neurourol Urodyn 29: 128–139.
33. Blanco Y. Compta Y. Graus F. Saiz A. (2008) Midbrain lesions and paroxysmal dysarthria in multiple sclerosis. Mult Scler 14: 694–697.
34. Bohannon R.W. Smith M.B. (1987) Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 67: 206–207.
35. Bozek C.B. Kastrukoff L.F. Wright J.M. Perry T.L. Larsen T.A. (1987) A controlled trial of isoniazid therapy for action tremor in multiple sclerosis. J Neurol 234: 36–39.
36. Bozzali M. Cercignani M. Sormani M.P. Comi G. Filippi M. (2002) Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am J Neuroradiol 23: 985–988.
37. Brenk A. Laun K. Haase C.G. (2008) Short-term cognitive training improves mental efficiency and mood in patients with multiple sclerosis. Eur Neurol 60: 304–309.
38. Brown R.F. Valpiani E.M. Tennant C.C. Dunn S.M. Sharrock M. Hodgkinson S. et al (2009) Longitudinal assessment of anxiety, depression, and fatigue in people with multiple sclerosis. Psychol Psychother 82: 41–56.
39. Brown T.R. Kraft G.H. (2005) Exercise and rehabilitation for individuals with multiple sclerosis. Phys Med Rehabil Clin N Am 16: 513–555.
40. Butefisch C. Hummelsheim H. Denzler P. Mauritz K.H. (1995) Repetitive training of isolated movements improves the outcome of motor rehabilitation of the centrally paretic hand. J Neurol Sci 130: 59–68.
41. Calcagno P. Ruoppolo G. Grasso M.G. de Vincentiis M. Paolucci S. (2002) Dysphagia in multiple sclerosis–prevalence and prognostic factors. Acta Neurol Scand 105: 40–43.
42. Canadian MS Research Group (1987) A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 14: 273–278.
43. Chia Y.W. Fowler C.J. Kamm M.A. Henry M.M. Lemieux M.C. Swash M. (1995) Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. J Neurol 242: 105–108.
44. Chiaravalloti N.D. de Luca J. (2002) Self-generation as a means of maximizing learning in multiple sclerosis: an application of the generation effect. Arch Phys Med Rehabil 83: 1070–1079.
45. Choudhuri I. Sarvananthan N. Gottlob I. (2007) Survey of management of acquired nystagmus in the United Kingdom. Eye (Lond) 21: 1194–1197.
46. Chwastiak L. Ehde D.M. Gibbons L.E. Sullivan M. Bowen J.D. Kraft G.H. (2002) Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry 159: 1862–1868.
47. Ciancio S.J. Mutchnik S.E. Rivera V.M. Boone T.B. (2001) Urodynamic pattern changes in multiple sclerosis. Urology 57: 239–245.
48. Cohen R.A. Fisher M. (1989) Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 46: 676–680.
49. Cohen S.M. Elackattu A. Noordzij J.P. Walsh M.J. Langmore S.E. (2009) Palliative treatment of dysphonia and dysarthria. Otolaryngol Clin North Am 42: 107–121. x.
50. Colosimo C. Millefiorini E. Grasso M.G. Vinci F. Fiorelli M. Koudriavtseva T. et al (1995) Fatigue in MS is associated with specific clinical features. Acta Neurol Scand 92: 353–355.
51. Comi G. Leocani L. Rossi P. Colombo B. (2001) Physiopathology and treatment of fatigue in multiple sclerosis. J Neurol 248: 174–179.
52. Creedon S.D. (1997) Intrathecal baclofen for severe spacticity: a meta-analysis. Int J Rehabil Health 3: 171–185.
53. Cutter N.C. Scott D.D. Johnson J.C. Whiteneck G. (2000) Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil 81: 164–169.
54. Dachille G. Ludovico G.M. Pagliarulo G. Vestita G. (2008) Sexual dysfunctions in multiple sclerosis. Minerva Urol Nefrol 60: 77–79.
55. Dalgas U. Stenager E. Jakobsen J. Petersen T. Hansen H.J. Knudsen C. et al (2009) Resistance training improves muscle strength and functional capacity in multiple sclerosis. Neurology 73: 1478–1484.
56. Dalgas U. Stenager E. Jakobsen J. Petersen T. Hansen H.J. Knudsen C. et al (2010) Fatigue, mood and quality of life improve in MS patients after progressive resistance training. Mult Scler 16: 480–490.
57. Daly D.D. Code C.F. Andersen H.A. (1962) Disturbances of swallowing and esophageal motility in patients with multiple sclerosis. Neurology 12: 250–256.
58. Dario A. Tomei G. (2004) A benefit–risk assessment of baclofen in severe spinal spasticity. Drug Saf 27: 799–818.
59. de Pauw A. Dejaeger E. D'hooghe B. Carton H. (2002) Dysphagia in multiple sclerosis. Clin Neurol Neurosurg 104: 345–351.
60. Demirkiran M. Sarica Y. Uguz S. Yerdelen D. Aslan K. (2006) Multiple sclerosis patients with and without sexual dysfunction: are there any differences? Mult Scler 12: 209–214.
61. Dennison L. Moss-Morris R. Chalder T. (2009) A review of psychological correlates of adjustment in patients with multiple sclerosis. Clin Psychol Rev 29: 141–153.
62. de Sousa E.A. Albert R.H. Kalman B. (2002) Cognitive impairments in multiple sclerosis: a review. Am J Alzheimers Dis Other Demen 17: 23–29.
63. Deuschl G. Bain P. Brin M. (1998) Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord 13(Suppl. 3): 2–23.
64. Dineen R.A. Vilisaar J. Hlinka J. Bradshaw C.M. Morgan P.S. Constantinescu C.S. et al (2009) Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis. Brain 132: 239–249.
65. DMKG Study Group (2003) Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J Neurol 250: 542–545.
66. Drake M.J. Fowler C.J. Griffiths D. Mayer E. Paton J.F. Birder L. (2010) Neural control of the lower urinary and gastrointestinal tracts: supraspinal CNS mechanisms. Neurourol Urodyn 29: 119–127.
67. Duncan G.W. Shahani B.T. Young R.R. (1976) An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. A double-blind, cross-over study. Neurology 26: 441–446.
68. Ehde D.M. Osborne T.L. Hanley M.A. Jensen M.P. Kraft G.H. (2006) The scope and nature of pain in persons with multiple sclerosis. Mult Scler 12: 629–638.
69. Eyssette M. Rohmer F. Serratrice G. Warter J.M. Boisson D. (1988) Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin 10: 699–708.
70. Fahn S. Tolosa E. Marin C. (1988) Clinical rating scale in tremor. In: Ed. Jankovic A. Tolosa E. (eds). Parkinson's Disease and Movement Disorders, Urban and Schwarzenberg: Munich, 225–234.
71. Feldman R.G. Kelly-Hayes M. Conomy J.P. Foley J.M. (1978) Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study. Neurology 28: 1094–1098.
72. Feys P. Helsen W. Liu X. Mooren D. Albrecht H. Nuttin B. et al (2005 a) Effects of peripheral cooling on intention tremor in multiple sclerosis. J Neurol Neurosurg Psychiatry 76: 373–379.
73. Feys P. Maes F. Nuttin B. Helsen W. Malfait V. Nagels G. et al (2005 b) Relationship between multiple sclerosis intention tremor severity and lesion load in the brainstem. Neuroreport 16: 1379–1382.
74. Filippi M. Rocca M.A. Colombo B. Falini A. Codella M. Scotti G. et al (2002) Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage 15: 559–567.
75. Fisher E. Lee J.C. Nakamura K. Rudick R.A. (2008) Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 64: 255–265.
76. Fisk J.D. Pontefract A. Ritvo P.G. Archibald C.J. Murray T.J. (1994 a) The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 21: 9–14.
77. Fisk J.D. Ritvo P.G. Ross L. Haase D.A. Marrie T.J. Schlech W.F. (1994 b) Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 18(Suppl. 1): S79–S83.
78. Flachenecker P. Rufer A. Bihler I. Hippel C. Reiners K. Toyka K.V. et al (2003) Fatigue in MS is related to sympathetic vasomotor dysfunction. Neurology 61: 851–853.
79. Fletcher S.G. Castro-Borrero W. Remington G. Treadaway K. Lemack G.E. Frohman E.M. (2009) Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management. Nat Clin Pract Urol 6: 96–107.
80. Fleuren J.F. Voerman G.E. Erren-Wolters C.V. Snoek G.J. Rietman J.S. Hermens H.J. et al (2010) Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry 81: 46–52.
81. Fowler C.J. Panicker J.N. Drake M. Harris C. Harrison S.C. Kirby M. et al (2009) A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 80: 470–477.
82. Fowler C.J. van Kerrebroeck P.E. Nordenbo A. van Poppel H. (1992) Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. Committee of the European Study Group of SUDIMS (Sexual and Urological Disorders in Multiple Sclerosis). J Neurol Neurosurg Psychiatry 55: 986–989.
83. Fragoso Y.D. da Silva E.O. Finkelsztejn A. (2009) Correlation between fatigue and self-esteem in patients with multiple sclerosis. Arq Neuropsiquiatr 67: 818–821.
84. Francis D.A. Grundy D. Heron J.R. (1986) The response to isoniazid of action tremor in multiple sclerosis and its assessment using polarised light goniometry. J Neurol Neurosurg Psychiatry 49: 87–89.
85. Fraser C. Mahoney J. McGurl J. (2008) Correlates of sexual dysfunction in men and women with multiple sclerosis. J Neurosci Nurs 40: 312–317.
86. Fredrikson S. Cheng Q. Jiang G.X. Wasserman D. (2003) Elevated suicide risk among patients with multiple sclerosis in Sweden. Neuroepidemiology 22: 146–152.
87. Frohman E.M. Kramer P.D. Dewey R.B. Kramer L. Frohman T.C. (2003) Benign paroxysmal positioning vertigo in multiple sclerosis: diagnosis, pathophysiology and therapeutic techniques. Mult Scler 9: 250–255.
88. Gajewski J.B. Awad S.A. (1986) Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 135: 966–968.
89. Gambi D. Rossini P.M. Calenda G. Rosetti S. Langoni A. Dantrolene A. (1983) Dantrolene sodium in the treatment of spasticity caused by multiple sclerosis or degenerative myelopathies: a double-blind, cross-over study in comparison with placebo. Curr Ther Res Clin Exp 33: 835–840.
90. Gelenberg A.J. Poskanzer D.C. (1973) The effect of dantrolene sodium on spasticity in multiple sclerosis. Neurology 23: 1313–1315.
91. Gentry T. (2008) PDAs as cognitive aids for people with multiple sclerosis. Am J Occup Ther 62: 18–27.
92. Ghez C. Thach W.T. (2000) The Cerebellum, McGraw-Hill Health Professions: New York,.
93. Ghotbi N. Ansari N.N. Naghdi S. Hasson S. Jamshidpour B. Amiri S. (2009) Inter-rater reliability of the Modified Modified Ashworth Scale in assessing lower limb muscle spasticity. Brain Inj 23: 815–819.
94. Giovannoni G. Thompson A.J. Miller D.H. Thompson E.J. (2001) Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology 57: 676–681.
95. Goldman Consensus Group (2005) The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 11: 328–337.
96. Goodman A.D. Brown T.R. Krupp L.B. Schapiro R.T. Schwid S.R. Cohen R. et al (2009) Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373: 732–738.
97. Goodman A.D. Cohen J.A. Cross A. Vollmer T. Rizzo M. Cohen R. et al (2007) Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 13: 357–368.
98. Goodwin R.J. Fowler C.G. (1997) Bladder, bowel and sexual dysfunction: recent advances. In: Ed. Thompson A.J. Polman C.H. Hohlfeld R. (eds). Multiple Sclerosis: Clinical Challenges and Controversies, Martin Dunitz: London, 265–281.
99. Govaert B. van Gemert W.G. Baeten C.G. (2009) Neuromodulation for functional bowel disorders. Best Pract Res Clin Gastroenterol 23: 545–553.
100. Goverover Y. Chiaravalloti N. de Luca J. (2008) Self-generation to improve learning and memory of functional activities in persons with multiple sclerosis: meal preparation and managing finances. Arch Phys Med Rehabil 89: 1514–1521.
101. Gracies J.M. (2001) Pathophysiology of impairment in patients with spasticity and use of stretch as a treatment of spastic hypertonia. Phys Med Rehabil Clin N Am 12: 747–768. vi.
102. Gronseth G. Cruccu G. Alksne J. Argoff C. Brainin M. Burchiel K. et al (2008) Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology 71: 1183–1190.
103. Gudziak M.R. Tiguert R. Puri K. Gheiler E.L. Triest J.A. (1999) Management of neurogenic bladder dysfunction with incontinent ileovesicostomy. Urology 54: 1008–1011.
104. Hakim E.A. Bakheit A.M. Bryant T.N. Roberts M.W. Intosh-Michaelis S.A. Spackman A.J. et al (2000) The social impact of multiple sclerosis–a study of 305 patients and their relatives. Disabil Rehabil 22: 288–293.
105. Haselkorn J.K. Balsdon R.C. Fry W.D. Herndon R.M. Johnson B. Little J.W. et al (2005) Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J Spinal Cord Med 28: 167–199.
106. Hazell P. O'Connell D. Heathcote D. Henry D. (2002) Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev CD002317–CD002317.
107. Henze T. (2005) Managing specific symptoms in people with multiple sclerosis. Int MS J 12: 60–68.
108. Henze T. Rieckmann P. Toyka K.V. (2006) Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol 56: 78–105.
109. Herrera-Guzmán I. Herrera-Abarca J.E. Gudayol-Ferré E. Herrera-Guzmán D. Gómez-Carbajal L. Peña-Olvira M. et al (2010) Effects of selective serotonin reuptake and dual serotonergic–noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res 177: 323–329.
110. Hinds J.P. Eidelman B.H. Wald A. (1990) Prevalence of bowel dysfunction in multiple sclerosis. A population survey. Gastroenterology 98: 1538–1542.
111. Hinds J.P. Wald A. (1989) Colonic and anorectal dysfunction associated with multiple sclerosis. Am J Gastroenterol 84: 587–595.
112. Hirsh A.T. Turner A.P. Ehde D.M. Haselkorn J.K. (2009) Prevalence and impact of pain in multiple sclerosis: physical and psychologic contributors. Arch Phys Med Rehabil 90: 646–651.
113. Hobart J.C. Riazi A. Thompson A.J. Styles I.M. Ingram W. Vickery P.J. et al (2006) Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 129: 224–234.
114. Hoffmann V. Kuhn W. Schimrigk S. Islamova S. Hellwig K. Lukas C. et al (2006) Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients. Eur J Neurol 13: 72–76.
115. Hoffmann V. Schimrigk S. Islamova S. Hellwig K. Lukas C. Brune N. et al (2003) Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. J Neurol Sci 211: 81–84.
116. Hooper J. Taylor R. Pentland B. Whittle I.R. (1998) Rater reliability of Fahn's tremor rating scale in patients with multiple sclerosis. Arch Phys Med Rehabil 79: 1076–1079.
117. Hsieh J.T. Wolfe D.L. Miller W.C. Curt A. (2008) Spasticity outcome measures in spinal cord injury: psychometric properties and clinical utility. Spinal Cord 46: 86–95.
118. Hudgson P. Weightman D. (1971) Baclofen in the treatment of spasticity. Br Med J 4: 15–17.
119. Hughes J.C. Enderby P.M. Langton Hewer R. (1994) Dysphagia and multiple sclerosis: a study and discussion of its nature and impact. Clin Rehabil 8: 18–26.
120. Huijbregts S.C. Kalkers N.F. de Sonneville L.M. de Groot V. Polman C.H. (2006) Cognitive impairment and decline in different MS subtypes. J Neurol Sci 245: 187–194.
121. Hyman N. Barnes M. Bhakta B. Cozens A. Bakheit M. Kreczy-Kleedorfer B. et al (2000) Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 68: 707–712.
122. Kalb R.C. Holland N. (2008) Urinary Dysfunction and MS: A Consumer Guide to Clinical Practice Guidelines, National Multiple Sclerosis Society.
123. Kalsi V. Fowler C.J. (2005) Therapy Insight: bladder dysfunction associated with multiple sclerosis. Nat Clin Pract Urol 2: 492–501.
124. Kalsi V. Gonzales G. Popat R. Apostolidis A. Elneil S. Dasgupta P. et al (2007) Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 62: 452–457.
125. Kanpolat Y. Berk C. Savas A. Bekar A. (2000) Percutaneous controlled radiofrequency rhizotomy in the management of patients with trigeminal neuralgia due to multiple sclerosis. Acta Neurochir (Wien) 142: 685–689.
126. Kaplan S.A. Goldfischer E.R. Steers W.D. Gittelman M. Andoh M. Forero-Schwanhaeuser S. (2010) Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes. Aging Male 13: 100–107.
127. Karatas M. (2008) Central vertigo and dizziness: epidemiology, differential diagnosis, and common causes. Neurologist 14: 355–364.
128. Kay G.G. Ebinger U. (2008) Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 62: 1792–1800.
129. Kaynak H. Altintas A. Kaynak D. Uyanik O. Saip S. Agaoglu J. et al (2006) Fatigue and sleep disturbance in multiple sclerosis. Eur J Neurol 13: 1333–1339.
130. Kesiktas N. Paker N. Erdogan N. Gulsen G. Bicki D. Yilmaz H. (2004) The use of hydrotherapy for the management of spasticity. Neurorehabil Neural Repair 18: 268–273.
131. Kessler T.M. Fowler C.J. Panicker J.N. (2009) Sexual dysfunction in multiple sclerosis. Expert Rev Neurother 9: 341–350.
132. Khan F. Ng L. Turner-Stokes L. (2009) Effectiveness of vocational rehabilitation intervention on the return to work and employment of persons with multiple sclerosis. Cochrane Database Syst Rev CD007256–CD007256.
133. Killestein J. Hoogervorst E.L. Reif M. Kalkers N.F. van Loenen A.C. Staats P.G. et al (2002) Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 58: 1404–1407.
134. Kindwall E.P. McQuillen M.P. Khatri B.O. Gruchow H.W. Kindwall M.L. (1991) Treatment of multiple sclerosis with hyperbaric oxygen. Results of a national registry. Arch Neurol 48: 195–199.
135. Kinnunen E. Wikstrom J. (1986) Prevalence and prognosis of epilepsy in patients with multiple sclerosis. Epilepsia 27: 729–733.
136. Knutsson E. Martensson A. Gransberg L. (1982) Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis. J Neurol Sci 53: 187–204.
137. Koch M. Mostert J. Heersema D. de Keyser J. (2007) Tremor in multiple sclerosis. J Neurol 254: 133–145.
138. Koch M. Uyttenboogaart M. Polman S. de Keyser J. (2008) Seizures in multiple sclerosis. Epilepsia 49: 948–953.
139. Koch M.W. Polman S.K. Uyttenboogaart M. de Keyser J. (2009) Treatment of seizures in multiple sclerosis. Cochrane Database Syst Rev CD007150–CD007150.
140. Koller W.C. (1984) Pharmacologic trials in the treatment of cerebellar tremor. Arch Neurol 41: 280–281.
141. Kondziolka D. Lunsford L.D. (2005) Percutaneous retrogasserian glycerol rhizotomy for trigeminal neuralgia: technique and expectations. Neurosurg Focus 18: E7–E7.
142. Krause P. Szecsi J. Straube A. (2007) FES cycling reduces spastic muscle tone in a patient with multiple sclerosis. NeuroRehabilitation 22: 335–337.
143. Krupp L.B. Alvarez L.A. LaRocca N.G. Scheinberg L.C. (1988) Fatigue in multiple sclerosis. Arch Neurol 45: 435–437.
144. Krupp L.B. Christodoulou C. Melville P. Scherl W.F. MacAllister W.S. Elkins L.E. (2004) Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 63: 1579–1585.
145. Krupp L.B. Coyle P.K. Doscher C. Miller A. Cross A.H. Jandorf L. et al (1995) Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 45: 1956–1961.
146. Lapierre Y. Bouchard S. Tansey C. Gendron D. Barkas W.J. Francis G.S. (1987) Treatment of spasticity with tizanidine in multiple sclerosis. Can J Neurol Sci 14: 513–517.
147. Laufens G. Poltz W. Reimann G. Schmiegelt F. Stempski S. (1998) Laufband- und Vojta-Physiotherapie an ausgewählten MS-Patienten – Ein Vergleich der Soforteffekte. Phys Rehab Kur Med 8: 174–177.
148. Lavano A. Volpentesta G. Aloisi M. Veltri C. Piragine G. Signorelli C.D. (2004) Use of chronic sacral nerve stimulation in neurological voiding disorders. J Neurosurg Sci 48: 157–159.
149. Leandri M. (2003) Therapy of trigeminal neuralgia secondary to multiple sclerosis. Expert Rev Neurother 3: 661–671.
150. Lebrun C. Alchaar H. Candito M. Bourg V. Chatel M. (2006) Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Mult Scler 12: 321–324.
151. Lechner H.E. Frotzler A. Eser P. (2006) Relationship between self- and clinically rated spasticity in spinal cord injury. Arch Phys Med Rehabil 87: 15–19.
152. Lobentanz I.S. Asenbaum S. Vass K. Sauter C. Klosch G. Kollegger H. et al (2004) Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand 110: 6–13.
153. Lyons K.E. Pahwa R. (2008) Deep brain stimulation and tremor. Neurotherapeutics 5: 331–338.
154. Malcomson K.S. Dunwoody L. Lowe-Strong A.S. (2007) Psychosocial interventions in people with multiple sclerosis: a review. J Neurol 254: 1–13.
155. Malhotra S. Pandyan A.D. Day C.R. Jones P.W. Hermens H. (2009) Spasticity, an impairment that is poorly defined and poorly measured. Clin Rehabil 23: 651–658.
156. Manconi M. Fabbrini M. Bonanni E. Filippi M. Rocca M. Murri L. et al (2007) High prevalence of restless legs syndrome in multiple sclerosis. Eur J Neurol 14: 534–539.
157. Manconi M. Rocca M.A. Ferini-Strambi L. Tortorella P. Agosta F. Comi G. et al (2008) Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage. Mult Scler 14: 86–93.
158. Manzoni G.C. Torelli P. (2005) Epidemiology of typical and atypical craniofacial neuralgias. Neurol Sci 26(Suppl. 2): s65–s67.
159. Martínez-Juárez I.E. López-Meza E. González-Aragón M.C. Ramírez-Bermúdez J. Corona T. (2009) Epilepsy and multiple sclerosis: Increased risk among progressive forms. Epilepsy Res 84: 250–253.
160. Mathiowetz V.G. Finlayson M.L. Matuska K.M. Chen H.Y. Luo P. (2005) Randomized controlled trial of an energy conservation course for persons with multiple sclerosis. Mult Scler 11: 592–601.
161. Matsumoto J. Morrow D. Kaufman K. Davis D. Ahlskog J.E. Walker A. et al (2001) Surgical therapy for tremor in multiple sclerosis: an evaluation of outcome measures. Neurology 57: 1876–1882.
162. Mecomber S.A. Herman R.M. (1971) Effects of local hypothermia on reflex and voluntary activity. Phys Ther 51: 271–281.
163. Mehrholz J. Wagner K. Meissner D. Grundmann K. Zange C. Koch R. et al (2005) Reliability of the Modified Tardieu Scale and the Modified Ashworth Scale in adult patients with severe brain injury: a comparison study. Clin Rehabil 19: 751–759.
164. Meneghetti G. Sparta S. Rusca F. Facco E. Martini A. Comacchio F. et al (1990) Hyperbaric oxygen therapy in the treatment of multiple sclerosis. A clinical and electrophysiological study in a 2 year follow-up. Riv Neurol 60: 67–71.
165. Miller L. Mattison P. Paul L. Wood L. (2007) The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis. Mult Scler 13: 527–533.
166. Mills R.J. Yap L. Young C.A. (2007) Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev CD005029–CD005029.
167. Mohr D.C. Boudewyn A.C. Goodkin D.E. Bostrom A. Epstein L. (2001) Comparative outcomes for individual cognitive-behavior therapy, supportive–expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol 69: 942–949.
168. Mohr D.C. Goodkin D.E. Likosky W. Gatto N. Baumann K.A. Rudick R.A. (1997) Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 54: 531–533.
169. Mohr D.C. Hart S.L. Julian L. Tasch E.S. (2007) Screening for depression among patients with multiple sclerosis: two questions may be enough. Mult Scler 13: 215–219.
170. Mohr D.C. Likosky W. Dwyer P. van der W.J. Boudewyn A.C. Goodkin D.E. (1999) Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis. Arch Neurol 56: 1263–1265.
171. Möller A. Wiedemann G. Rohde U. Backmund H. Sonntag A. (1994) Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psychiatr Scand 89: 117–121.
172. Monster A.W. (1974) Spasticity and the effect of dantrolene sodium. Arch Phys Med Rehabil 55: 373–383.
173. Moreira N.C. Damasceno R.S. Medeiros C.A. Bruin P.F. Teixeira C.A. Horta W.G. et al (2008) Restless leg syndrome, sleep quality and fatigue in multiple sclerosis patients. Braz J Med Biol Res 41: 932–937.
174. Mostert S. Kesselring J. (2002) Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Mult Scler 8: 161–168.
175. Motl R.W. Gosney J.L. (2008) Effect of exercise training on quality of life in multiple sclerosis: a meta-analysis. Mult Scler 14: 129–135.
176. Motl R.W. McAuley E. Snook E.M. Gliottoni R.C. (2009) Physical activity and quality of life in multiple sclerosis: intermediary roles of disability, fatigue, mood, pain, self-efficacy and social support. Psychol Health Med 14: 111–124.
177. Motl R.W. Suh Y. Weikert M. (2010) Symptom cluster and quality of life in multiple sclerosis. J Pain Symptom Manage 42 (4): 212–216.
178. Mueller M.E. Gruenthal M. Olson W.L. Olson W.H. (1997) Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil 78: 521–524.
179. Multiple Sclerosis Council for Clinical Practice Guidelines (1998) Fatigue and Multiple Sclerosis: Evidence-Based Management Strategies, Washington DC: Paralyzed Veterans Of America.
180. Mumenthaler M. Mattle H. (2008) Neurologie, Thieme Verlag: Stuttgart,.
181. Murray T.J. (1985) Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 12: 251–254.
182. Neuhauser H.K. Lempert T. (2009) Vertigo: epidemiologic aspects. Semin Neurol 29: 473–481.
183. Nicoletti A. Sofia V. Biondi R. Lo F.S. Reggio E. Patti F. et al (2003) Epilepsy and multiple sclerosis in Sicily: a population-based study. Epilepsia 44: 1445–1448.
184. Norton C. Chelvanayagam S. (2010) Bowel problems and coping strategies in people with multiple sclerosis. Br J Nurs 19: 220–226.
185. Nurmikko T.J. Gupta S. Maclver K. (2010) Multiple sclerosis-related central pain disorders. Curr Pain Headache Rep 14: 189–195.
186. Nyquist P.A. Cascino G.D. McClelland R.L. Annegers J.F. Rodriguez M. (2002) Incidence of seizures in patients with multiple sclerosis: a population-based study. Mayo Clin Proc 77: 910–912.
187. Nyquist P.A. Cascino G.D. Rodriguez M. (2001) Seizures in patients with multiple sclerosis seen at Mayo Clinic, Rochester, Minn, 1990–1998. Mayo Clin Proc 76: 983–986.
188. O'Brien A.R. Chiaravalloti N. Goverover Y. de Luca J. (2008) Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. Arch Phys Med Rehabil 89: 761–769.
189. O'Brien M.T. (1993) Multiple sclerosis: the relationship among self-esteem, social support, and coping behavior. Appl Nurs Res 6: 54–63.
190. O'Connor A.B. Schwid S.R. Herrmann D.N. Markman J.D. Dworkin R.H. (2008) Pain associated with multiple sclerosis: systematic review and proposed classification. Pain 137: 96–111.
191. Oken B.S. Kishiyama S. Zajdel D. Bourdette D. Carlsen J. Haas M. et al (2004) Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology 62: 2058–2064.
192. Olafsson E. Benedikz J. Hauser W.A. (1999) Risk of epilepsy in patients with multiple sclerosis: a population-based study in Iceland. Epilepsia 40: 745–747.
193. Onal B. Siva A. Buldu I. Demirkesen O. Cetinel B. (2009) Voiding dysfunction due to multiple sclerosis: a large scale retrospective analysis. Int Braz J Urol 35: 326–333.
194. Paci M. (2003) Physiotherapy based on the Bobath concept for adults with post-stroke hemiplegia: a review of effectiveness studies. J Rehabil Med 35: 2–7.
195. Paisley S. Beard S. Hunn A. Wight J. (2002) Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Mult Scler 8: 319–329.
196. Panicker J. Haslam C. (2009) Lower urinary tract dysfunction in MS: management in the community. Br J Community Nurs 14: 474–480.
197. Pardo G. Boutwell C. Conner J. Denney D. Oleen-Burkey M. (2010) Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate. J Neurosci Nurs 42: 40–46.
198. Parmenter B.A. Weinstock-Guttman B. Garg N. Munschauer F. Benedict R.H. (2007) Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test. Mult Scler 13: 52–57.
199. Patten S.B. Beck C.A. Williams J.V. Barbui C. Metz L.M. (2003) Major depression in multiple sclerosis: a population-based perspective. Neurology 61: 1524–1527.
200. Patten S.B. Francis G. Metz L.M. Lopez-Bresnahan M. Chang P. Curtin F. (2005) The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler 11: 175–181.
201. Patten S.B. Williams J.V. Metz L.M. (2008) Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis. Mult Scler 14: 406–411.
202. Penn R.D. Savoy S.M. Corcos D. Latash M. Gottlieb G. Parke B. et al (1989) Intrathecal baclofen for severe spinal spasticity. N Engl J Med 320: 1517–1521.
203. Penner I.K. Raselli C. Stocklin M. Opwis K. Kappos L. Calabrese P. (2009) The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler 15: 1509–1517.
204. Perlman S.L. (2000) Cerebellar ataxia. Curr Treat Options Neurol 2: 215–224.
205. Pittock S.J. McClelland R.L. Mayr W.T. Rodriguez M. Matsumoto J.Y. (2004) Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population. Mov Disord 19: 1482–1485.
206. Pöllmann W. Feneberg W. Steinbrecher A. Haupts M.R. Henze T. (2005) [Therapy of pain syndromes in multiple sclerosis–an overview with evidence-based recommendations]. Fortschr Neurol Psychiatr 73: 268–285.
207. Polman C.H. Bertelsmann F.W. de Waal R. van Diemen H.A. Uitdehaag B.M. van Loenen A.C. et al (1994 a) 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol 51: 1136–1139.
208. Polman C.H. Bertelsmann F.W. van Loenen A.C. Koetsier J.C. (1994 b) 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 51: 292–296.
209. Preziosi G. Emmanuel A. (2009) Neurogenic bowel dysfunction: pathophysiology, clinical manifestations and treatment. Expert Rev Gastroenterol Hepatol 3: 417–423.
210. Priebe M.M. Sherwood A.M. Thornby J.I. Kharas N.F. Markowski J. (1996) Clinical assessment of spasticity in spinal cord injury: a multidimensional problem. Arch Phys Med Rehabil 77: 713–716.
211. Pucci E. Branas P. D'Amico R. Giuliani G. Solari A. Taus C. (2007) Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev CD002818–CD002818.
212. Putzki N. Pfriem A. Limmroth V. Yaldizli O. Tettenborn B. Diener H.C. et al (2009) Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis. Eur J Neurol 16: 262–267.
213. Radziszewski P. Crayton R. Zaborski J. Czlonkowska A. Borkowski A. Bossowska A. et al (2009) Multiple sclerosis produces significant changes in urinary bladder innervation which are partially reflected in the lower urinary tract functional status-sensory nerve fibers role in detrusor overactivity. Mult Scler 15: 860–868.
214. Rae-Grant A.D. Eckert N.J. Bartz S. Reed J.F. (1999) Sensory symptoms of multiple sclerosis: a hidden reservoir of morbidity. Mult Scler 5: 179–183.
215. Rammohan K.W. Rosenberg J.H. Lynn D.J. Blumenfeld A.M. Pollak C.P. Nagaraja H.N. (2002) Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 72: 179–183.
216. Rao S.M. Leo G.J. Bernardin L. Unverzagt F. (1991 a) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41: 685–691.
217. Rao S.M. Leo G.J. Ellington L. Nauertz T. Bernardin L. Unverzagt F. (1991 b) Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 41: 692–696.
218. Rasova K. Feys P. Henze T. van Tongeren H. Cattaneo D. Jonsdottir J. et al (2010) Emerging evidence-based physical rehabilitation for multiple sclerosis–towards an inventory of current content across Europe. Health Qual Life Outcomes 8: 76–77.
219. Rekand T. (2010) Clinical assessment and management of spasticity: a review. Acta Neurol Scand Suppl: 190: 62–66.
220. Rivera-Navarro J. Benito-León J. Oreja-Guevara C. Pardo J. Dib W.B. Orts E. et al (2009) Burden and health-related quality of life of Spanish caregivers of persons with multiple sclerosis. Mult Scler 15: 1347–1355.
221. Roelcke U. Kappos L. Lechner-Scott J. Brunnschweiler H. Huber S. Ammann W. et al (1997) Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 48: 1566–1571.
222. Rogers J.M. Panegyres P.K. (2007) Cognitive impairment in multiple sclerosis: evidence-based analysis and recommendations. J Clin Neurosci 14: 919–927.
223. Rossini P.M. Pasqualetti P. Pozzilli C. Grasso M.G. Millefiorini E. Graceffa A. et al (2001) Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 7: 354–358.
224. Rougier M.B. Tilikete C. (2008) [Ocular motor disorders in multiple sclerosis]. J Fr Ophtalmol 31: 717–721.
225. Rucker J.C. (2008) An update on acquired nystagmus. Semin Ophthalmol 23: 91–97.
226. Ruud Bosch J.L. Groen J. (1996) Treatment of refractory urge urinary incontinence with sacral spinal nerve stimulation in multiple sclerosis patients. Lancet 348: 717–719.
227. Sabra A.F. Hallett M. Sudarsky L. Mullally W. (1982) Treatment of action tremor in multiple sclerosis with isoniazid. Neurology 32: 912–913.
228. Sachais B.A. Logue J.N. Carey M.S. (1977) Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. Arch Neurol 34: 422–428.
229. Sadovnick A.D. Remick R.A. Allen J. Swartz E. Yee I.M. Eisen K. et al (1996) Depression and multiple sclerosis. Neurology 46: 628–632.
230. Sander J.W. (2003) The epidemiology of epilepsy revisited. Curr Opin Neurol 16: 165–170.
231. Sandyk R. (1995) The pineal gland, cataplexy, and multiple sclerosis. Int J Neurosci 83: 153–163.
232. Sauter C. Zebenholzer K. Hisakawa J. Zeitlhofer J. Vass K. (2008) A longitudinal study on effects of a six-week course for energy conservation for multiple sclerosis patients. Mult Scler 14: 500–505.
233. Sawa G.M. Paty D.W. (1979) The use of baclofen in treatment of spasticity in multiple sclerosis. Can J Neurol Sci 6: 351–354.
234. Schmidt R.T. Lee R.H. Spehlmann R. (1976) Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurol Neurosurg Psychiatry 39: 350–356.
235. Schuurman P.R. Bosch D.A. Merkus M.P. Speelman J.D. (2008) Long-term follow-up of thalamic stimulation versus thalamotomy for tremor suppression. Mov Disord 23: 1146–1153.
236. Schwid S.R. Petrie M.D. Murray R. Leitch J. Bowen J. Alquist A. et al (2003) A randomized controlled study of the acute and chronic effects of cooling therapy for MS. Neurology 60: 1955–1960.
237. Schyns F. Paul L. Finlay K. Ferguson C. Noble E. (2009) Vibration therapy in multiple sclerosis: a pilot study exploring its effects on tone, muscle force, sensation and functional performance. Clin Rehabil 23: 771–781.
238. Sechi G.P. Zuddas M. Piredda M. Agnetti V. Sau G. Piras M.L. et al (1989) Treatment of cerebellar tremors with carbamazepine: a controlled trial with long-term follow-up. Neurology 39: 1113–1115.
239. Shakespeare D.T. Boggild M. Young C. (2003) Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev CD001332–CD001332.
240. Shaygannejad V. Janghorbani M. Ashtari F. Zanjani H.A. Zakizade N. (2008) Effects of rivastigmine on memory and cognition in multiple sclerosis. Can J Neurol Sci 35: 476–481.
241. Sheean G.L. Murray N.M. Rothwell J.C. Miller D.H. Thompson A.J. (1998) An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain 121: 967–975.
242. Shifren J.L. (2004) The role of androgens in female sexual dysfunction. Mayo Clin Proc 79: S19–S24.
243. Shvarts P.G. Kadykov A.S. Shvedkov V.V. Timerbaeva S.L. Polevaia E.V. Mulach A.N. (2009) [Experience with application of trospium chloride in patients with neurogenic detrusor overactivity]. Urologia 5: 24–29.
244. Sloane P.D. (1989) Dizziness in primary care. Results from the National Ambulatory Medical Care Survey. J Fam Pract 29: 33–38.
245. Smith C. Birnbaum G. Carter J.L. Greenstein J. Lublin F.D. (1994) Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology 44: S34–S42.
246. Smolenski C. Muff S. Smolenski-Kautz S. (1981) A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opin 7: 374–383.
247. Snow B.J. Tsui J.K. Bhatt M.H. Varelas M. Hashimoto S.A. Calne D.B. (1990) Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 28: 512–515.
248. Sokic D.V. Stojsavljevic N. Drulovic J. Dujmovic I. Mesaros S. Ercegovac M. et al (2001) Seizures in multiple sclerosis. Epilepsia 42: 72–79.
249. Solaro C. Lunardi G.L. Mancardi G.L. (2003) Pain and MS. Int MS J 10: 14–19.
250. Stankoff B. Waubant E. Confavreux C. Edan G. Debouverie M. Rumbach L. et al (2005) Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 64: 1139–1143.
251. Stanton B.R. Barnes F. Silber E. (2006) Sleep and fatigue in multiple sclerosis. Mult Scler 12: 481–486.
252. Starck M. Albrecht H. Pöllmann W. Dieterich M. Straube A. (2010) Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. J Neurol 257: 322–327.
253. Storey E. Tuck K. Hester R. Hughes A. Churchyard A. (2004) Inter-rater reliability of the International Cooperative Ataxia Rating Scale (ICARS). Mov Disord 19: 190–192.
254. Strupp M. Schuler O. Krafczyk S. Jahn K. Schautzer F. Buttner U. et al (2003) Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology 61: 165–170.
255. Sullivan M.J. Weinshenker B. Mikail S. Bishop S.R. (1995) Screening for major depression in the early stages of multiple sclerosis. Can J Neurol Sci 22: 228–231.
256. Tardieu G. Shentoub S. Delarue R. (1954) [Research on a technic for measurement of spasticity.]. Rev Neurol (Paris) 91: 143–144.
257. Tekok-Kilic A. Benedict R.H. Weinstock-Guttman B. Dwyer M.G. Carone D. Srinivasaraghavan B. et al (2007) Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. Neuroimage 36: 1294–1300.
258. Tellez N. Alonso J. Rio J. Tintore M. Nos C. Montalban X. et al (2008) The basal ganglia: a substrate for fatigue in multiple sclerosis. Neuroradiology 50: 17–23.
259. Tepavcevic D.K. Kostic J. Basuroski I.D. Stojsavljevic N. Pekmezovic T. Drulovic J. (2008) The impact of sexual dysfunction on the quality of life measured by MSQoL-54 in patients with multiple sclerosis. Mult Scler 14: 1131–1136.
260. Thomas F.J. Wiles C.M. (1999) Dysphagia and nutritional status in multiple sclerosis. J Neurol 246: 677–682.
261. Thurtell M.J. Joshi A.C. Leone A.C. Tomsak R.L. Kosmorsky G.S. Stahl J.S. et al (2010) Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. Ann Neurol 67: 676–680.
262. Timmermann L. Deuschl G. Fogel W. Hilker R. Kupsch A. Lange M. et al (2009) [Deep brain stimulation for tremor in multiple sclerosis: consensus recommendations of the German Deep Brain Stimulation Association]. Nervenarzt 80: 673–677.
263. Trouillas P. Takayanagi T. Hallett M. Currier R.D. Subramony S.H. Wessel K. et al (1997) International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 145: 205–211.
264. Vahter L. Kreegipuu M. Talvik T. Gross-Paju K. (2007) One question as a screening instrument for depression in people with multiple sclerosis. Clin Rehabil 21: 460–464.
265. van Diemen H.A. Polman C.H. van Dongen M.M. Nauta J.J. Strijers R.L. van Loenen A.C. et al (1993) 4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. J Neurol Sci 116: 220–226.
266. Vaney C. Heinzel-Gutenbrunner M. Jobin P. Tschopp F. Gattlen B. Hagen U. et al (2004) Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 10: 417–424.
267. Vercellino M. Masera S. Lorenzatti M. Condello C. Merola A. Mattioda A. et al (2009) Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol 68: 489–502.
268. Vereecken R.L. van Poppel H. Boeckx G. Leruitte A. (1983) Long-term alpha-adrenergic-blocking therapy in detrusor-urethra dyssynergia. Eur Urol 9: 167–169.
269. Villoslada P. Arrondo G. Sepulcre J. Alegre M. Artieda J. (2009) Memantine induces reversible neurologic impairment in patients with MS. Neurology 72: 1630–1633.
270. Wade D.T. Collin C. Stott C. Duncombe P. (2010) Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 16: 707–714.
271. Wade D.T. Makela P. Robson P. House H. Bateman C. (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10: 434–441.
272. Walker I.D. Gonzalez E.W. (2007) Review of intervention studies on depression in persons with multiple sclerosis. Issues Ment Health Nurs 28: 511–531.
273. Wall L.L. (1990) The management of detrusor instability. Clin Obstet Gynecol 33: 367–377.
274. Wang J.L. Reimer M.A. Metz L.M. Patten S.B. (2000) Major depression and quality of life in individuals with multiple sclerosis. Int J Psychiatry Med 30: 309–317.
275. Weinshenker B.G. Issa M. Baskerville J. (1996) Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study. Arch Neurol 53: 353–358.
276. Weinshenker B.G. Penman M. Bass B. Ebers G.C. Rice G.P. (1992) A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 42: 1468–1471.
277. Weiss N. North R.B. Ohara S. Lenz F.A. (2003) Attenuation of cerebellar tremor with implantation of an intrathecal baclofen pump: the role of gamma-aminobutyric acidergic pathways. Case report. J Neurosurg 99: 768–771.
278. Whitaker J.N. Mitchell G.W. (1997) Clinical features of multiple sclerosis. In: Ed. Raine C.S. McFarland H.F. Tourtellotte W.W. (eds). Multiple Sclerosis: Clinical and Pathogenic Basis, Chapman & Hall: London, 3–19.
279. Wiesel P.H. Norton C. Glickman S. Kamm M.A. (2001) Pathophysiology and management of bowel dysfunction in multiple sclerosis. Eur J Gastroenterol Hepatol 13: 441–448.
280. Wiesel P.H. Norton C. Roy A.J. Storrie J.B. Bowers J. Kamm M.A. (2000) Gut focused behavioural treatment (biofeedback) for constipation and faecal incontinence in multiple sclerosis. J Neurol Neurosurg Psychiatry 69: 240–243.
281. Wiesner W. Wetzel S.G. Kappos L. Hoshi M.M. Witte U. Radue E.W. et al (2002) Swallowing abnormalities in multiple sclerosis: correlation between videofluoroscopy and subjective symptoms. Eur Radiol 12: 789–792.
282. Wiles C.M. Newcombe R.G. Fuller K.J. Shaw S. Furnival-Doran J. Pickersgill T.P. et al (2001) Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry 70: 174–179.
283. Wingerchuk D.M. Benarroch E.E. O'Brien P.C. Keegan B.M. Lucchinetti C.F. Noseworthy J.H. et al (2005) A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 64: 1267–1269.
284. Wishart H.A. Roberts D.W. Roth R.M. McDonald B.C. Coffey D.J. Mamourian A.C. et al (2003) Chronic deep brain stimulation for the treatment of tremor in multiple sclerosis: review and case reports. J Neurol Neurosurg Psychiatry 74: 1392–1397.
285. Yap L. Kouyialis A. Varma T.R. (2007) Stereotactic neurosurgery for disabling tremor in multiple sclerosis: thalamotomy or deep brain stimulation? Br J Neurosurg 21: 349–354.
286. Zajicek J. Fox P. Sanders H. Wright D. Vickery J. Nunn A. et al (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362: 1517–1526.
287. Ziemssen T. (2009) Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci 277(Suppl. 1): S37–S41.
288. Zifko U.A. Rupp M. Schwarz S. Zipko H.T. Maida E.M. (2002) Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 249: 983–987.
289. Zorro O. Lobato-Polo J. Kano H. Flickinger J.C. Lunsford L.D. Kondziolka D. (2009) Gamma knife radiosurgery for multiple sclerosis-related trigeminal neuralgia. Neurology 73: 1149–1154.
290. Zorzon M. Zivadinov R. Bosco A. Bragadin L.M. Moretti R. Bonfigli L. et al (1999) Sexual dysfunction in multiple sclerosis: a case–control study. I. Frequency and comparison of groups. Mult Scler 5: 418–427.